Results 271 to 280 of about 467,609 (357)

The Global Burden of Leukemia, 1990–2021: A Systematic Analysis of Prevalence, DALYs, and Risk Factors From the Global Burden of Disease Study

Med Research, EarlyView.
Using data from the Global Burden of Disease Study 2021, we systematically assessed leukemia prevalence and disability‐adjusted life years (DALYs) across 204 countries and territories from 1990 to 2021, stratified by subtype, demographics, and risk factors.
Yuping Wu, Haini Zhang, Shuang Luo, Xiangmei Zhang, Mei Tan, Jinmei Chen, Pei Huang, Yan Chen, Zuochen Du   +8 more
wiley   +1 more source

Epigenetic silencing of transposable elements by IRF2BP2 is a selective dependency of myeloid leukemia

Xu J, Whittle J, Clayfield L, Lie-a-ling M, Leddy EA, Smith D, Sellers R, Deniz O, Lacaud G.   +8 more
europepmc   +1 more source

Population Pharmacokinetics of Radotinib in Healthy Volunteers and Patients with Chronic Myeloid Leukemia. [PDF]

Pharmaceuticals (Basel)
Kang M, Kim J, Lee Y, Shin JS, Park MS, Jiang Q, Chung EK, Lee JI.   +7 more
europepmc   +1 more source

Machine Learning for Predictive Modeling in Nanomedicine‐Based Cancer Drug Delivery

Med Research, EarlyView.
The integration of AI/ML into nanomedicine offers a transformative approach to therapeutic design and optimization. Unlike conventional empirical methods, AI/ML models (such as classification, regression, and neural networks) enable the analysis of complex clinical and formulation datasets to predict optimal nanoparticle characteristics and therapeutic
Rohan Chand Sahu, Sanchit Arora, Dinesh Kumar, Ashish Kumar Agrawal   +3 more
wiley   +1 more source

Real-world treatment and utilization of venetoclax for incident acute myeloid leukemia in a Medicare population. [PDF]

Future Oncol
Roth JA, D'Amico PG, Cappelleri JC, Donckels EA, Yu A, Okunev I, Petrilla A, Purcell S, Ma J, Russell A.   +9 more
europepmc   +1 more source

Megakaryocytes in chronic phase of chronic myeloid leukemia: A descriptive case series

, 2016
Arun Kumar Arunachalam, Mili Jain, Ashutosh Kumar, Rashmi Kushwaha, Uma Shankar Singh, Anil Kumar Tripathi   +5 more
openalex   +1 more source

CRISPR Enabled Precision Oncology: From Gene Editing to Tumor Microenvironment Remodeling

Med Research, EarlyView.
CRISPR technology has progressed from a prokaryotic immune system to a diverse suite of editing platforms, including Cas nucleases, base and prime editors, and RNA‐targeting enzymes. These advances enable precise genomic and epigenomic interventions, high‐throughput functional screening, and immune engineering.
Kailai Li, Peixin Huang, Yue Qian, Anqi Lin, Jingjun He, Junyi Shen, Li Chen, Kai Miao, Jian Zhang   +8 more
wiley   +1 more source

Restoring p53 wild-type conformation in TP53-Y220C-mutant acute myeloid leukemia. [PDF]

Blood
Carter BZ, Mak PY, Ayoub E, Wu X, Ke B, Nishida Y, Futreal A, Ostermann LB, Bedoy AD, Boettcher S, DiNardo CD, Puzio-Kuter A, Poyurovsky MV, Levine A, Andreeff M.   +14 more
europepmc   +1 more source

The Contribution of Cholesterol and Squalene Synthase in Cancer: Molecular Mechanisms, Lipid Rafts and Therapeutic Approaches

Medicinal Research Reviews, EarlyView.
ABSTRACT A plethora of cellular signaling pathways are dysregulated in cancer cells, promoting carcinogenesis and migration. Cholesterol has recently been linked to cancer by several subcellular mechanisms, especially by its involvement in the formation of lipid rafts, which promote oncogenic signaling and cancer cell invasion. Squalene synthase (SQS),
Danai Mavridi, Theodora Katavati, Angeliki P. Kourounakis   +2 more
wiley   +1 more source

The Imbalanced Patterns and Clinical Significance of Cytokines in Acute Myeloid Leukemia Microenvironment. [PDF]

Immun Inflamm Dis
Wang R, Jing K, Zhao H, Zheng G, Cai J.
europepmc   +1 more source